Additive effects of combined application of multiple herg blockers

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 6, 2008, Pages 549-552

  Margulis, Michael ^a   Sorota, Steve ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Arrhythmia; Cardiac; HERG blockers

Indexed keywords

BEKM 1; CISAPRIDE; DRUG ADDITIVE; FLUVOXAMINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG BLOCKER; QUINIDINE; UNCLASSIFIED DRUG; BEKM 1 TOXIN; BEKM-1 TOXIN; KCNH2 PROTEIN, HUMAN; SCORPION VENOM;

ANIMAL CELL; ARRHYTHMOGENESIS; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL EVALUATION; DRUG BINDING; DRUG BINDING SITE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EXTRACELLULAR SPACE; HEART ARRHYTHMIA; HYDROPHOBICITY; IN VITRO STUDY; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; VESTIBULE; VOLTAGE CLAMP; WHOLE CELL; ANIMAL; CULTURE TECHNIQUE; DRUG ANTAGONISM; HUMAN; MOUSE;

ANIMALS; CELL CULTURE TECHNIQUES; CISAPRIDE; DRUG SYNERGISM; ETHER-A-GO-GO POTASSIUM CHANNELS; FLUVOXAMINE; HUMANS; MICE; PATCH-CLAMP TECHNIQUES; QUINIDINE; SCORPION VENOMS;

EID: 53249145866     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31817532ee     Document Type: Article

References (15)

1. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219-233.
2. Brendorp B, Pedersen O, Torp-Pedersen C, et al. A benefit-risk assessment of class III antiarrhythmic agents. Drug Saf. 2002;25:847-865.
3. Doyle DA, Morais Cabral J, Pfuetzner RA, et al. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science. 1998;280:69-77.
4. Jiang Y, Lee A, Chen J, et al. The open pore conformation of potassium channels. Nature. 2002;417:523-526.
5. Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA. 2000;97:12329-12333.
6. Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci. 2005;26:119-124.
7. Milnes JT, Crociani O, Arcangeli A, et al. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol. 2003;139:887-898.
8. Korolkova YV, Tseng GN, Grishin EV. Unique interaction of scorpion toxins with the hERG channel. J Mol Recognit. 2004;17:209-217.
9. Ducroq J, Printemps R, Le Grand M. Additive effects of ziprasidone and D, L-sotalol on the action potential in rabbit Purkinje fibres and on the hERG potassium current. J Pharmacol Toxicol Methods. 2005;52:115-122.
10. Anumonwo JM, Horta J, Delmar M, et al. Proton and zinc effects on HERG currents. Biophys J. 1999;77:282-298.
11. Hamill OP, Marty A, Neher E, et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391:85-100.
12. Zhang M, Korolkova YV, Liu J, et al. BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1. Biophys J. 2003;84:3022-3036.
13. Mohammad S, Zhou Z, Gong Q, et al. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol. 1997;273:H2534-H2538.
14. Paul AA, Witchel HJ, Hancox JC. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol. 2002;136:717-729.
15. Abbott GW, Xu X, Roepke TK. Impact of ancillary subunits onventricular repolarization. J Electrocardiol. 2007;40:S42-S46.